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Background Two markers of cerebral small vessel disease are
white matter hyperintensities and cerebral microbleeds, which
commonly occur in people with Alzheimer’s disease.
Aim and/or hypothesis To test for independent associations
between two Alzheimer’s disease-susceptibility gene loci –
APOE ε and the TOMM40 ‘523’ poly-T repeat – and white
matter hyperintensities/cerebral microbleed burden in
community-dwelling older adults.
Methods Participants in the Lothian Birth Cohort 1936 under-
went genotyping for APOE ε and TOMM40 523, and detailed
structural brain magnetic resonance imaging at a mean age of
72·70 years (standard deviation = 0·7; range = 71–74).
Results No significant effects of APOE ε or TOMM40 523 geno-
types on white matter hyperintensities or cerebral microbleed
burden were found amongst 624 participants.
Conclusions Lack of association between two Alzheimer’s
disease susceptibility gene loci and markers of cerebral small
vessel disease may reflect the relative health of this popula-
tion compared with those in other studies in the literature.
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Introduction
There is evidence that the presence of cardiovascular disease
pathology can increase the future risk of Alzheimer’s disease (AD)
and cognitive decline (1). White matter hyperintensities (WMH)
and cerebral microbleeds (CMB) are generally considered to
reflect cerebrovascular burden in ageing. They are manifestations
and markers of cerebral small-vessel disease and often co-occur
(2).
The mechanisms underlying significant association between
cardiovascular and neurodegenerative pathology are unclear;
however, there are three main hypotheses (1). Firstly, it is possible
that cardiovascular diseases and AD/cognitive decline share
common risk factors and are not mechanistically related (1).
Secondly, it is possible that cardiovascular burden may expedite
progression of AD/cognitive decline through promoting athero-
sclerosis and accumulations of amyloid-beta plaques, and/or
(thirdly) by increasing vulnerability to such pathology and low-
ering the threshold at which cognitive decline becomes apparent
behaviorally, even in the absence of a mechanistic link (1,3).
Two genetic risk factors for AD and age-related cognitive
decline are in the APOE and TOMM40 gene loci (4). Two recent
meta-analyses reported no overall significant association between
APOE ε4 and WMH in older adults (P > 0·05). Paternoster et al.
(5) did not stratify analyses by whether participants were gener-
ally healthy or not (total n = 8546), whereas Schilling et al. (6) did
(‘healthy’n = 8405). However, these reports were not independent
because some common data were included in both. In contrast,
two meta-analyses reported a significant association between
APOE ε4 and CMB: Schilling et al. (6) (‘healthy’ n = 5387;
P = 0·002) and Maxwell et al. (7) (total n = 7351; P < 0·01). These
two reports also had a degree of overlapping datasets. A more
recent individual study (8) reported similar results (n = 1965,
P < 0·05).
In the above reports, the positive association between APOE ε4
and CMB burden was not completely consistent; other genetic
predictor variables may exert independent effects. The TOMM40
rs10524523 (‘523’) variable length poly-T repeat has been signifi-
cantly associated with brain phenotypes such as cognitive decline,
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independent of APOE genotype (9). The TOMM40 523 locus is
characterized by a variable number of T residues (poly-T repeats)
that can be grouped into ‘short’ (<20; ‘S’), ‘long’ (20–29; ‘L’), and
‘very long’ (≥30; ‘VL’) (10). Roses (11) plotted histograms
showing the distributions of poly-T repeat lengths in different
APOE genotypes: ε3/ε3, ε3/ε4, and ε4/ε4. The poly-T repeat was
strongly linked with the APOE ε haplotype; ε4 is linked to L, with
ε3 linked to either S or VL alleles (4); investigating the effects of
TOMM40 523 genotype on brain-related phenotypes may explain
some of the heterogeneity in the possible APOE ε4 and WMH/
CMB association. This study therefore aims to contribute a large
amount of relevant genetic APOE/TOMM40 and WMH/CMB




The Lothian Birth Cohort 1936 (LBC1936) is a longitudinal
sample of generally healthy community-dwelling older adults
(12). All participants were born in 1936, and most resided in the
Edinburgh area of Scotland in older age. The sample received
detailed cognitive, medical, and demographic assessments at the
Wellcome Trust Clinical Research Facility (Edinburgh; http://
www.wtcrf.ed.ac.uk) at age ∼73 years. Participants underwent
detailed brain MRI around the same time (13) (mean inter-
val = 65·0 days, SD = 39·5). Of the 866 LBC1936 participants that
attended clinic assessment, 700 completed neuroimaging (mean
age = 72·70, SD = 0·7). Details of LBC1936 recruitment and
assessment, including aspects of possible selection bias and attri-
tion, can be found in two cohort protocol papers by Deary et al.
(12,14).
Participants were genotyped by TaqMan assay for APOE ε
(Applied Biosystems, Carlsbad, CA, USA) using DNA isolated
from whole blood (12). TOMM40 523 was genotyped by the
laboratory of Dr. Ornit Chiba-Falek (Duke University) as
described previously (15).
Brain MRI
Participants underwent whole brain structural MRI, acquired
using a GE Signa Horizon 1·5 T HDxt clinical scanner (General
Electric, Milwaukee, WI, USA) equipped with a self-shielding
gradient set (33 mT/m maximum gradient strength) and
manufacturer-supplied eight-channel phased-array head coil,
lasting around 70 min. In addition to standard structural T2-,
T2*-, and FLAIR-weighted MRI, the imaging protocol included a
high-resolution T1-weighted volume sequence acquired in the
coronal plane with field-of-view of 256 × 256 mm, imaging
matrix 192 × 192 (zero-filled to 256 × 256), 160 1·3-mm thick
slices giving 1 × 1 × 1·3-mm voxel dimensions (13). The repeti-
tion, echo, and inversion times were 10, 4, and 500 ms respec-
tively. The detailed protocol for WMH/CMB image processing,
and intracranial/total brain volume measurement, is published by
Wardlaw et al. (13). WMH volumes were calculated from binary
masks generated by an in-house-developed and validated soft-
ware tool written in MATLAB that applies a technique named
Multispectral Colouring Modulation and Variance Identification:
1936 [MCMxxxVI (16)]. Visual scoring of WMH was also per-
formed using the Fazekas scale by experienced neuroradiologists.
Microhemorrhages (i.e. CMBs) were coded for number and
distribution using a simplified version of the Brain Observer
MicroBleed Scale [BOMBS (17)], which considers microbleeds as
small homogenous round foci of low signal intensity on T2*-
weighted images, of less than 10 mm in diameter. This rating scale
is used to record the number of observed definite or possible
microbleeds in the right/left hemispheres, delineated into bleeds
<5 mm and 5–10 mm. Because of the relatively low frequency of
CMB’s in the LBC1936 sample, we examined the presence of ≥1
definite/possible microbleeds, strictly lobar microbleeds, strictly
deep or infratentorial microbleeds. Any significant findings were
reanalyzed as definite microbleeds only.
Inter- and intra-rater reliability standards have been reported
in previous work (13). Genotyping was performed blind to
imaging (and vice versa). Imaging lesions were defined according
to STRIVE recommendations (2). Of the 700 participants that
completed brain MRI, 25 had one or more lacunar infarcts, and
given this low frequency, we did not consider this variable further.
Statistical analysis
Age in days and gender were included as covariates. An online
calculator was used to perform tests of Hardy–Weinberg
equilibrium and determine minor allele frequencies (http://
www.had2know.com/academics/hardy-weinberg-equilibrium-
calculator-3-alleles.html). Volumetric WMH data were
transformed with a natural logarithmic function to provide a
more normal distribution. Data were analyzed with the IBM SPSS
statistics program (version 17; IBM, Armonk, NY, USA).
Univariate general linear models tested the effects of separate
APOE and TOMM40 genotypes upon imaging variables. Specifi-
cally, the effects of APOE ε4 ‘risk’ allele presence vs. absence (i.e.
ε2/ε4; ε3/ε4; ε4/ε4 vs. ε2/ε2; ε2/ε3; ε3/ε3) were tested. To assess
the independent effects of TOMM40 523 genotype, we tested for
effects of S allele frequency vs. pooled L/VL alleles (simply L*; S/S
vs. S/L* vs. L*/L*) in participants with the ‘neutral’ APOE
ε3/ε3 genotype (9) and then in the ε3/ε4 genotype subgroup,
because TOMM40 523 genotype may interact with the ε4 allele
(18).
Results
Of the 866 LBC1936 participants that attended clinic assessment,
700 completed neuroimaging. Participants were excluded from
analysis if they had Mini-Mental State Exam scores below 24 or
had not completed the test (19). [A cutoff of 24 was used because
this is considered the lowest possible score within the range of ‘no
cognitive impairment’, and is a common approach (20).]. This left
694 participants, of whom 624 and 636 had successful genotyping
for APOE ε and TOMM40 523, respectively. Allele frequencies
were in Hardy–Weinberg equilibrium for APOE (ε2 = 7·4%,
ε3 = 77·0%; ε4 = 15·6%) and TOMM40 (S = 40·9%, L = 15·3%,
and VL = 43·9%; both P > 0·05). Allele frequencies are shown in
Table S1.
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There were no significant associations between APOE ε4 pres-
ence (vs. absence), or TOMM40 523 genotype (in any analyses),
and WMH/CMB variables (all P > 0·05; Tables S2–S3).
Discussion
Our findings align with previous meta-analyses in observing no
significant APOE/WMH association (5,6). In terms of CMB, this
report does not align with recent meta-analyses that concluded
significant deleterious effects of APOE ε4 (6,7). Of those meta-
analyses, Schilling et al. (6) observed a significant effect of APOE
ε4 in general populations only – and not in pooled samples with
neurological or vascular disorders; the lack of association in
LBC1936 may be because of the relatively good health of the
sample. Our findings do align with two individual studies of
generally healthy older adults (included in the meta-analyses)
which reported no significant APOE ε4 present (vs. absent) effects
[by Sveinbjornsdottir et al. (21) (n = 1725) and Jeerakathil et al.
(22) (n = 368)]. There was no evidence of an independent effect
of TOMM40 523 genotype here.
Previous significant associations in individual CMB reports
may perhaps reflect a degree of type 1 error, particularly in
smaller samples. Several studies report broader age ranges than
examined here (71–74 years; SD = 0·7) (7). Any effect of age on
CMB may be via processes associated with age; controlling for age
statistically is unlikely to completely eradicate these effects (23),
so wide age ranges could possibly contribute to spurious genetic
associations.
The BOMBS instrument allows raters to note CMBs as either
definite or possible [a cautious category to avoid misclassifica-
tions of mimics (17)]. It would be interesting to examine if pre-
viously reported significant APOE-CMB associations are affected
when analyzed to incorporate possible microbleeds/mimics.
It is possible that the sample size examined here is not suffi-
ciently powered to detect any possibly modest effects of APOE or
TOMM40 genotypes on WMH/CMB (5). It is possible that the
LBC1936 sample is generally healthier when compared with other
samples, exacerbated by a selection bias where healthier partici-
pants were more likely to attend brain MRI assessment (24).
Generally, the LBC1936 sample is slightly restricted in range
towards the upper end of general mental ability and socioeco-
nomic status (14). In addition, APOE ε4 genotype has previously
been associated with earlier mortality and cardiovascular disease
(25): it is possible that a selection bias exists whereby healthier
participants are more likely to attend cognitive or brain imaging
assessment, and this may contribute to our finding no effect of
APOE/TOMM40 genotypes on WMH/CMB phenotypes with
MRI.
Maxwell et al. (7) estimated with a ‘fail-safe N calculation’ that
null studies including at least 7700 participants would be required
to attenuate their meta-analysis APOE ε4/CMB association
(reported P = 0·01) to non-significance (i.e. P > 0·05). Further
independent studies will help to define the more exact nature and
strength of any APOE/CMB association in generally healthy
populations.
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